FIMECS Presents IRAK-M Protein Degraders for Immuno-oncology at theAACR Annual Meeting 2019
Kanagawa, Japan, 28, February 2019 - FIMECS, Inc. (“FIMECS”) a private biotechnology company
creating a new class of drugs based on targeted protein degradation, today announced researchdemonstrating drug discovery activity of the company’s first-in-class hetero-bifunctional molecules tospecifically degrade IRAK-M protein. Data were presented at the American Association for Cancer
Research (AACR) Annual Meeting 2019 in Atlanta, GA, U.S.A., March 29–April 3, 2019.
Title:”Targeted IRAK-M degradation as a novel and efficacious cancer-immunotherapy
overcoming innate-driven immunosuppression”

Presenters: Kanae Gamo, Naomi Kitamoto, Yoshihide Tomata, Yusuke Tominari
Session category: Immunology
Session title: Molecular Mechanisms in the Immune Response to Cancer
Time and date: 13:00–17:00 (local time), Monday, April 1, 2019
Place: Georgia World Congress Center, Exhibit Hall B, Poster Section 24
Poster board No.: 8Poster No.: 2354
Presentation abstract: https://www.abstractsonline.com/pp8/#!/6812/presentation/5189
IRAK-M has an important role in tightly controlling innate immune responsiveness to preserve
homeostasis, mediating immune tolerance, and acts as a negative feedback regulator of TLR/IL-1R
signaling pathway. Targeting IRAK-M, which expression is restricted to myeloid cells, would be
potentially limiting adverse events against non-target tissues. From supporting evidence for the role ofIRAK-M in innate immunosuppressive capacity of tumor-associated macrophages (TAMs) or dendritic
cells (DCs), we have developed compounds targeting IRAK-M as an effective cancer-immunotherapy
strategy.
FIMECS discovered multiple drug candidates within a year by applying the company’s platform
technology “RaPPIDSTM. In the poster presentation, the company presents in vitro mode of action
analysis and in vivo studies of IRAK-M degraders.
“This is an exciting milestone for immuno-oncology research area with a novel mechanism.” said
Yusuke Tominari, PhD, CEO and CSO, FIMECS “IRAK-M degraders are unprecedented strategy forcancer-immunotherapy and provides a potentially transformative approach to the treatment of cancer
with high unmet medical needs including non-small cell lung cancer (NSCLC).About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drugcandidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase
binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients allover the world through various internal and collaboration projects. https://www.fimecs.com/eng/

About RaPPIDS™
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery
platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform
allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how
and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target proteinbinders, linkers, and E3 ligase binders.

###FIMECS, Inc. Media and Investor Contact:
Yusuke Kohno,
CFO and VP of Corporate Development
Tel: +81-50-5328-9458
Email: info@fimecs.com